SYSTEMS AND METHODS FOR MULTIVARIATE ANALYSIS OF ADVERSE EVENT DATA
The present disclosure describes systems and methods for multivarlate analysis of adverse event data. According to a first aspect, patient-specific genomic Information is used to optimize or de-risk therapy for the patient. According to other aspects of the invention, unknown drug targets are identified via adverse event data. According to still other espects, a medication is identified to exclude from use for an indication or from a clinical trial of another medication. According to another aspect, a predicted side effect profile is generated for a medication targeting a novel target. According to still another aspect, combination therapies are identified via adverse event data. According to another aspect, molecular interactions between a plurality of molecular entities are displayed in an intuitive format. According to still another aspect, molecular entities responsible for adverse event differences between similar indications are identified. According to still another aspect, genetic variants associated with adverse events in a clinical trial are identified.
1 - 127 . (canceled)
128 . A method for identifying unknown drug targets via adverse event data, comprising:
receiving, by an analyzer module executed by a processor of a computing device from a user, an identification of a first drug;
identifying, by the analyzer module from a medication information database stored in a computer-readable storage medium, a second drug related to the first drug;
retrieving, by the analyzer module from an adverse event database stored in the computer-readable storage medium, a first side effect profile associated with the first drug, and a second side effect profile associated with the second drug;
generating, by the analyzer module, a third side effect profile comprising a subset of the first side effect profile not shared by the second side effect profile;
identifying, by the analyzer module from the adverse event database, a third drug having a fourth side effect profile comprising the third side effect profile;
retrieving, by the analyzer module from the medication information database, a list of one or more targets of the first drug not targeted by the second drug; and
presenting, by the analyzer module via a display interface of the computing device to the user, the retrieved list of one or more targets as potential targets of the third drug.
129 . The method of claim 128 , wherein the second drug is in the same class as the first drug.
130 . The method of claim 128 , wherein the first drug and second drug are identified as binding to at least one common target.
131 . The method of claim 128 , wherein each of the first, second, and fourth side effect profiles comprise a statistical index of side effects experienced by consumers of the corresponding first, second, and third drugs.
132 . The method of claim 128 , wherein generating the third side effect profile comprises subtracting a frequency of occurrence of a side effect in the second side effect profile from a frequency of occurrence of the side effect in the first side effect profile.
133 . The method of claim 128 , wherein generating the third side effect profile comprises identifying a side effect with a first frequency of occurrence in the first side effect profile and a second frequency of occurrence in the second side effect profile.
134 . The method of claim 133 , further comprising excluding the identified side effect from the third side effect profile, responsive to the first frequency of occurrence being within a predetermined threshold from the second frequency of occurrence.
135 . The method of claim 133 , further comprising including the identified side effect in the third side effect profile, responsive the first frequency of occurrence being outside a predetermined threshold from the second frequency of occurrence.
136 . The method of claim 128 , wherein identifying a third drug having a fourth side effect profile comprises identifying a side effect with a first frequency of occurrence in the third side effect profile and a second frequency of occurrence in the fourth side effect profile, the first frequency of occurrence and second frequency of occurrence being within a predetermined threshold.
137 . The method of claim 128 , further comprising treating indications associated with the potential targets via the third drug or identifying a patient having a genomic variant resulting in a patient's altered activity of the one or more potential targets of the third drug, and indicating the third drug is indicated or contraindicated for the patient.
138 . A system for identifying unknown drug targets via adverse event data, comprising:
a computing device, in communication with a computer-readable storage medium comprising an adverse event database and a medication information database, comprising a display interface and a processor executing an analyzer module configured for:
receiving, from a user, an identification of a first drug; identifying, from the medication information database, a second drug related to the first drug;
retrieving, from the adverse event database, a first side effect profile associated with the first drug, and a second side effect profile associated with the second drug;
generating a third side effect profile comprising a subset of the first side effect profile not shared by the second side effect profile;
identifying, from the adverse event database, a third drug having a fourth side effect profile comprising the third side effect profile;
retrieving, from the medication information database, a list of one or more targets of the first drug not targeted by the second drug; and
presenting, via the display interface to the user, the retrieved list of one or more targets as potential targets of the third drug.
139 . The system of claim 138 , wherein the second drug is in the same class as the first drug.
140 . The system of claim 138 , wherein the first drug and second drug are identified as binding to at least one common target.
141 . The system of claim 138 , wherein each of the first, second, and fourth side effect profiles comprise a statistical index of side effects experienced by consumers of the corresponding first, second, and third drugs.
142 . The system of claim 138 , wherein the analyzer module is further configured for subtracting a frequency of occurrence of a side effect in the second side effect profile from a frequency of occurrence of the side effect in the first side effect profile.
143 . The system of claim 138 , wherein the analyzer module is further configured for identifying a side effect with a first frequency of occurrence in the first side effect profile and a second frequency of occurrence in the second side effect profile.
144 . The system of claim 143 , wherein the analyzer module is further configured for excluding the identified side effect from the third side effect profile, responsive to the first frequency of occurrence being within a predetermined threshold from the second frequency of occurrence.
145 . The system of claim 138 , wherein the analyzer module is further configured for including the identified side effect in the third side effect profile, responsive the first frequency of occurrence being outside a predetermined threshold from the second frequency of occurrence.
146 . The system of claim 138 , wherein the analyzer module is further configured for identifying a side effect with a first frequency of occurrence in the third side effect profile and a second frequency of occurrence in the fourth side effect profile, the first frequency of occurrence and second frequency of occurrence being within a predetermined threshold.
147 . The system of claim 138 , wherein the analyzer module is further configured for presenting, via the display interface to the user, an advise of treatment of indications associated with the potential targets via the third drug or identifying a patient having a genomic variant resulting in a patient's altered activity of the one or more potential targets of the third drug, and presenting, via the display interface to the user, an indication that the third drug is indicated or contraindicated for the patient.
148 - 197 . (canceled)